These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

582 related articles for article (PubMed ID: 26092496)

  • 1. Adverse events and adherence to HIV post-exposure prophylaxis: a cohort study at the Korle-Bu Teaching Hospital in Accra, Ghana.
    Tetteh RA; Nartey ET; Lartey M; Mantel-Teeuwisse AK; Leufkens HG; Nortey PA; Dodoo AN
    BMC Public Health; 2015 Jun; 15():573. PubMed ID: 26092496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Side effects and tolerability of post-exposure prophylaxis with zidovudine, lamivudine, and lopinavir/ritonavir: a comparative study with HIV/AIDS patients.
    Cai J; Xiao J; Zhang Q
    Chin Med J (Engl); 2014; 127(14):2632-6. PubMed ID: 25043080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes of a Postexposure Prophylaxis Program at the Korle-Bu Teaching Hospital in Ghana: A Retrospective Cohort Study.
    Tetteh RA; Nartey ET; Lartey M; Mantel-Teeuwisse AK; Leufkens HG; Nortey PA; Dodoo AN
    J Int Assoc Provid AIDS Care; 2015; 14(6):544-52. PubMed ID: 24162616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of adherence to HIV Post-Exposure Prophylaxis protocol among frontline healthcare workers at the Ho Teaching Hospital, Ghana.
    Suglo RE; Aku FY; Anaman-Torgbor JA; Tarkang EE
    Int J Infect Dis; 2021 May; 106():208-212. PubMed ID: 33812009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiretroviral therapy (ART) for treating HIV infection in ART-eligible pregnant women.
    Sturt AS; Dokubo EK; Sint TT
    Cochrane Database Syst Rev; 2010 Mar; (3):CD008440. PubMed ID: 20238370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of adverse events associated with antiretroviral regimens for postexposure prophylaxis for occupational and nonoccupational exposures to prevent transmission of human immunodeficiency virus.
    Luque A; Hulse S; Wang D; Shahzad U; Tanzman E; Antenozzi S; Smith B
    Infect Control Hosp Epidemiol; 2007 Jun; 28(6):695-701. PubMed ID: 17520543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Post-exposure prophylaxis of HIV infection in out-patient clinic of hospital for infectious diseases in Warsaw in 2001-2002].
    Kowalska JD; Firlag-Burkacka E; Niezabitowska M; Bakowska E; Ignatowska A; Pulik P; Horban A
    Przegl Epidemiol; 2006; 60(4):789-94. PubMed ID: 17682761
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Choice of antiretroviral drugs for postexposure prophylaxis for children: a systematic review.
    Penazzato M; Dominguez K; Cotton M; Barlow-Mosha L; Ford N
    Clin Infect Dis; 2015 Jun; 60 Suppl 3():S177-81. PubMed ID: 25972500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Longer prior exposure to zidovudine/lamivudine-containing combination antiretroviral therapy, age, and male gender are each associated with reduced subcutaneous adipose tissue.
    Vrouenraets SM; Wit FW; Garcia EF; Huber M; Brinkman K; Moyle G; Domingo P; Tarr PE; Podzamczer D; Ristola M; Gatell JM; Livrozet JM; Furrer H; Reiss P;
    HIV Clin Trials; 2012; 13(2):103-10. PubMed ID: 22510357
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A pilot study to assess the immunologic and virologic efficacy of generic nevirapine, zidovudine and lamivudine in the treatment of HIV-1 infected women with pre-exposure to single dose nevirapine or short course zidovudine and their spouses in Chitungwiza, Zimbabwe.
    Zijenah LS; Kadzirange G; Rusakaniko S; Kufa T; Gonah N; Tobaiwa O; Gwanzura C; Matsikire E; Katzenstein DA
    Cent Afr J Med; 2006; 52(1-2):1-8. PubMed ID: 17892232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiretroviral post-exposure prophylaxis (PEP) for occupational HIV exposure.
    Young TN; Arens FJ; Kennedy GE; Laurie JW; Rutherford Gw
    Cochrane Database Syst Rev; 2007 Jan; 2007(1):CD002835. PubMed ID: 17253483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of HIV Postexposure Prophylaxis in healthcare workers after occupational exposure: a Thai university hospital setting.
    Kiertiburanakul S; Wannaying B; Tonsuttakul S; Kehachindawat P; Apivanich S; Somsakul S; Malathum K
    J Med Assoc Thai; 2006 Jul; 89(7):974-8. PubMed ID: 16881429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adherence to Post-Exposure Prophylaxis (PEP) and Incidence of HIV Seroconversion in a Major North American Cohort.
    Thomas R; Galanakis C; Vézina S; Longpré D; Boissonnault M; Huchet E; Charest L; Murphy D; Trottier B; Machouf N
    PLoS One; 2015; 10(11):e0142534. PubMed ID: 26559816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post exposure prophylaxis following occupational exposure to HIV: a survey of health care workers in Mbeya, Tanzania, 2009-2010.
    Mponela MJ; Oleribe OO; Abade A; Kwesigabo G
    Pan Afr Med J; 2015; 21():32. PubMed ID: 26405468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experience of healthcare workers taking postexposure prophylaxis after occupational HIV exposures: findings of the HIV Postexposure Prophylaxis Registry.
    Wang SA; Panlilio AL; Doi PA; White AD; Stek M; Saah A
    Infect Control Hosp Epidemiol; 2000 Dec; 21(12):780-5. PubMed ID: 11140914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of 6-week Neonatal Triple-combination Antiretroviral Postexposure Prophylaxis in High-risk HIV-exposed Infants.
    Anugulruengkitt S; Suntarattiwong P; Ounchanum P; Srirompotong U; Jantarabenjakul W; Sophonphan J; Punnahitanon S; Pancharoen C; Cressey TR; Chokephaibulkit K; Puthanakit T;
    Pediatr Infect Dis J; 2019 Oct; 38(10):1045-1050. PubMed ID: 31365477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Post-exposure prophylaxis for HIV infection: a clinical trial comparing lopinavir/ritonavir versus atazanavir each with zidovudine/lamivudine.
    Diaz-Brito V; León A; Knobel H; Peraire J; Domingo P; Clotet B; Dalmau D; Cruceta A; Arnaiz JA; Gatell JM; García F;
    Antivir Ther; 2012; 17(2):337-46. PubMed ID: 22293542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Evaluation of tolerance of zidovudine-lamivudine-nevirapine combination in HIV 1 patients in Fann Teaching Hospital in Dakar].
    Fortes Déguénonvo L; Diop SA; Leye MM; Seydi M; Dieng AB; Bentaleb H; Diouf A; Lakhe NA; Ka D; Cisse VM; Dia Badiane NM; Manga MN; Ndour CT; Soumaré M; Diop BM; Sow PS
    Bull Soc Pathol Exot; 2013 Oct; 106(4):244-7. PubMed ID: 24150730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First line zidovudine/lamivudine/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavir.
    van Vonderen MG; Lips P; van Agtmael MA; Hassink EA; Brinkman K; Geerlings SE; Sutinen J; Ristola M; Danner SA; Reiss P
    AIDS; 2009 Jul; 23(11):1367-76. PubMed ID: 19424051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A pilot study to evaluate the safety and feasibility of the administration of AZT/3TC fixed dose combination to HIV infected pregnant women and their infants in Rio de Janeiro, Brazil.
    Lambert JS; Nogueira SA; Abreu T; Machado ES; Costa TP; Bondarovsky M; Andrade M; Halpern M; Barbosa R; Perez M
    Sex Transm Infect; 2003 Dec; 79(6):448-52. PubMed ID: 14663118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.